Literature DB >> 21838781

The effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome.

Dhaval Nanavati1, Daniel R Austin, Lisa A Catapano, David A Luckenbaugh, Ayse Dosemeci, Husseini K Manji, Guang Chen, Sanford P Markey.   

Abstract

Bipolar disorder is a devastating illness that is marked by recurrent episodes of mania and depression. There is growing evidence that the disease is correlated with disruptions in synaptic plasticity cascades involved in cognition and mood regulation. Alleviating the symptoms of bipolar disorder involves chronic treatment with mood stabilizers like lithium or valproate. These two structurally dissimilar drugs are known to alter prominent signaling cascades in the hippocampus, but their effects on the post-synaptic density complex remain undefined. In this work, we utilized mass spectrometry for quantitative profiling of the rat hippocampal post-synaptic proteome to investigate the effects of chronic mood stabilizer treatment. Our data show that in response to chronic treatment of mood stabilizers there were not gross qualitative changes but rather subtle quantitative perturbations in post-synaptic density proteome linked to several key signaling pathways. Our data specifically support the changes in actin dynamics on valproate treatment. Using label-free quantification methods, we report that lithium and valproate significantly altered the abundance of 21 and 43 proteins, respectively. Seven proteins were affected similarly by both lithium and valproate: Ank3, glutamate receptor 3, dynein heavy chain 1, and four isoforms of the 14-3-3 family. Immunoblotting the same samples confirmed the changes in Ank3 and glutamate receptor 3 abundance. Our findings support the hypotheses that BPD is a synaptic disorder and that mood stabilizers modulate the protein signaling complex in the hippocampal post-synaptic density. Published 2011. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21838781      PMCID: PMC3192943          DOI: 10.1111/j.1471-4159.2011.07424.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  81 in total

1.  Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium.

Authors:  N L Johnston-Wilson; C D Sims; J P Hofmann; L Anderson; A D Shore; E F Torrey; R H Yolken
Journal:  Mol Psychiatry       Date:  2000-03       Impact factor: 15.992

2.  Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia.

Authors:  S H Fatemi; J A Earle; J M Stary; S Lee; J Sedgewick
Journal:  Neuroreport       Date:  2001-10-29       Impact factor: 1.837

3.  Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.

Authors:  C J Phiel; F Zhang; E Y Huang; M G Guenther; M A Lazar; P S Klein
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

4.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

5.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia.

Authors:  Y Hakak; J R Walker; C Li; W H Wong; K L Davis; J D Buxbaum; V Haroutunian; A A Fienberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

6.  Enhancement of hippocampal neurogenesis by lithium.

Authors:  G Chen; G Rajkowska; F Du; N Seraji-Bozorgzad; H K Manji
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

7.  The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.

Authors:  J Cartmell; J A Monn; D D Schoepp
Journal:  Eur J Pharmacol       Date:  2000-07-21       Impact factor: 4.432

8.  CASK participates in alternative tripartite complexes in which Mint 1 competes for binding with caskin 1, a novel CASK-binding protein.

Authors:  Katsuhiko Tabuchi; Thomas Biederer; Stefan Butz; Thomas C Sudhof
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

9.  RIM binding proteins (RBPs) couple Rab3-interacting molecules (RIMs) to voltage-gated Ca(2+) channels.

Authors:  H Hibino; R Pironkova; O Onwumere; M Vologodskaia; A J Hudspeth; F Lesage
Journal:  Neuron       Date:  2002-04-25       Impact factor: 17.173

10.  Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex.

Authors:  Scott E Hemby; Stephen D Ginsberg; Brian Brunk; Steven E Arnold; John Q Trojanowski; James H Eberwine
Journal:  Arch Gen Psychiatry       Date:  2002-07
View more
  18 in total

Review 1.  Ankyrins: Roles in synaptic biology and pathology.

Authors:  Katharine R Smith; Peter Penzes
Journal:  Mol Cell Neurosci       Date:  2018-05-03       Impact factor: 4.314

2.  The novel caspase-3 substrate Gap43 is involved in AMPA receptor endocytosis and long-term depression.

Authors:  Meng-Hsuan Han; Song Jiao; Jie-Min Jia; Yong Chen; Cai Yun Chen; Marjan Gucek; Sanford P Markey; Zheng Li
Journal:  Mol Cell Proteomics       Date:  2013-09-10       Impact factor: 5.911

Review 3.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

4.  AnkG hemizygous mice present cognitive impairment and elevated anxiety/depressive-like traits associated with decreased expression of GABA receptors and postsynaptic density protein.

Authors:  Cui Liu; Ling Zhang; Jie Wu; Xiaolong Sui; Yanfeng Xu; Lan Huang; Yunlin Han; Hua Zhu; Yanhong Li; Xiuping Sun; Chuan Qin
Journal:  Exp Brain Res       Date:  2017-08-18       Impact factor: 1.972

Review 5.  Dendritic structural plasticity and neuropsychiatric disease.

Authors:  Marc P Forrest; Euan Parnell; Peter Penzes
Journal:  Nat Rev Neurosci       Date:  2018-03-16       Impact factor: 34.870

Review 6.  Translational genomics and beyond in bipolar disorder.

Authors:  Chen Zhang; Xiao Xiao; Tao Li; Ming Li
Journal:  Mol Psychiatry       Date:  2020-05-18       Impact factor: 15.992

7.  Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder.

Authors:  Francesco Benedetti; Irene Bollettini; Ignazio Barberi; Daniele Radaelli; Sara Poletti; Clara Locatelli; Adele Pirovano; Cristina Lorenzi; Andrea Falini; Cristina Colombo; Enrico Smeraldi
Journal:  Neuropsychopharmacology       Date:  2012-09-19       Impact factor: 7.853

8.  Psychiatric risk factor ANK3/ankyrin-G nanodomains regulate the structure and function of glutamatergic synapses.

Authors:  Katharine R Smith; Katherine J Kopeikina; Jessica M Fawcett-Patel; Katherine Leaderbrand; Ruoqi Gao; Britta Schürmann; Kristoffer Myczek; Jelena Radulovic; Geoffrey T Swanson; Peter Penzes
Journal:  Neuron       Date:  2014-10-22       Impact factor: 17.173

9.  Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology.

Authors:  Melanie P Leussis; Jon M Madison; Tracey L Petryshen
Journal:  Biol Mood Anxiety Disord       Date:  2012-10-01

10.  Homer1 promotes dendritic spine growth through ankyrin-G and its loss reshapes the synaptic proteome.

Authors:  Sehyoun Yoon; Nicolas H Piguel; Natalia Khalatyan; Leonardo E Dionisio; Jeffrey N Savas; Peter Penzes
Journal:  Mol Psychiatry       Date:  2021-01-04       Impact factor: 13.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.